Back HIV Prevention

BHIVA 2015: HIV Treatment Outcomes No Better with Single-tablet Regimens than Individual Pills

One-pill-a-day HIV treatments such as Atripla, Stribild, Complera, and Triumeq and Triumeq have the same rates of virological failure, drug resistance, and side effects as multiple tablet regimens, according to a meta-analysis presented to the British HIV Association (BHIVA) conference this week in Brighton. Single tablets cost the UK National Health Service (NHS) 5 five times more but have unproven clinical benefits, said Andrew Hill of Chelsea and Westminster Hospital.

alt

Read more:

BHIVA 2015: Many People with HIV Willing to Take Part in Cure Research Despite its Risks

There is a strong interest among people living with HIV in research towards an HIV cure, with many potential participants willing to consider antiretroviral treatment interruption. Respondents to a survey presented at the British HIV Association (BHIVA) conference this week in Brighton generally understood that they would be unlikely to benefit personally from cure research. Priorities for a cure were to eliminate health problems and the risk of HIV transmission, rather than necessarily testing HIV-negative.

alt

Read more:

April 10 is National Youth HIV & AIDS Awareness Day

April 10 is the third observation of National Youth HIV & AIDS Awareness Day (NYHAAD), an opportunity to promote education and raise awareness about the epidemic among young people in the U.S.

alt

Read more:

CROI 2015: Cardiovascular Risk Factors for HIV-Positive People

Consistent with past research, an analysis from New York City has shown that people with HIV are at higher risk for death due to cardiovascular disease, although this risk is declining, according to a report at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI). Several other studies looked at cardiovascular risk factors in this population, including inflammatory biomarkers, chronic kidney disease, gut bacteria, and use of abacavir.

altCardiovascular Mortality

Several previous observational studies have found that cardiovascular disease (CVD) and associated events such as heart attacks and strokes are more common among HIV-positive people compared to the HIV-negative general population. But the relationship between heart disease and HIV infection itself, inflammation and metabolic abnormalities, antiretroviral drug toxicities, and traditional risk factors such as smoking is not fully understood.

David Hanna from Albert Einstein College of Medicine and colleagues assessed changing CVD mortality rates among people with HIV in New Your City (abstract 729). The analysis included all HIV-positive people age 13 or older between 2001 and 2012, as reported to the New York City HIV Surveillance Registry. Surveillance data were linked with the city's Vital Statistics Registry and National Death Index to determine how many people with HIV died due to major CVD-related events.

The study included 145,009 HIV-positive people, who contributed nearly 1,227,000 total person-years of data; 71% were men and the median age was 49 years. Between 2001 and 2012, a total of 29,326 deaths occurred. Overall mortality declined over time, mostly due to fewer HIV/AIDS-related deaths.

During this period, about one-tenth of all deaths among people with HIV were attributed to major CVD events, including ischemic heart disease events such as myocardial infarction (42% of CVD deaths), hypertensive or high blood pressure disease (27%), and cerebrovascular events such as stroke (10%).

However, while the proportion of deaths due to CVD rose during this period from 7% to 13% -- because fewer people were dying of AIDS and other causes -- the actual cardiovascular mortality rate for people with HIV fell over time. Cardiovascular mortality in the general population declined as well, from 47% to 39%.

Overall, after adjusting for other factors including sex, race/ethnicity, and year, people with HIV had a 54% higher CVD death rate than HIV-negative people. CVD mortality was significantly higher for people with HIV in all age groups through age 65. Among older people, CVD mortality was similar or higher in the general population. While HIV-positive people with both detectable viral load and those with viral suppression had higher CVD death rates than HIV-negatives, those whose latest HIV RNA measurement was <400 copies/mL had a significantly lower rate than those with higher viral load (3.9 vs 7.7 per 1000 person-year, respectively).

"CVD deaths constitute an increasing share of deaths among HIV-diagnosed persons," the researchers concluded. "HIV care providers should emphasize preventive measures to reduce CVD risk such as smoking cessation, blood pressure control, and lipid management."

Inflammation and Gut Flora

In recent years there has been a growing emphasis on the detrimental effects of chronic inflammation and immune activation in people with HIV, even those with sustained viral suppression. As previously reported, this was the theme of a CROI plenary talk by Steven Grinspoon of Massachsuetts General Hospital and Harvard Medical School (abstract 134).

Inflammation and immune activation may result from low-level residual viral replication even in people with undetectable plasma viral load using standard clinical tests.

In an analysis of the large NA-ACCORD trial, Daniel Drozd from the University of Washington and colleagues (abstract 748) found that detectable HIV viral load, a history of AIDS-defining illness, and lower CD4 T-cell count were independent predictors of myocardial infarction, or heart attack. Similarly, Jorge Salinas from Emory University and colleagues (abstract 746) showed that cumulative HIV viremia and CD4 count over time -- not just at a single time-point -- predicted risk of myocardial infarction in the Veterans Aging Cohort Study.

Another potential trigger of inflammation is microbial translocation, or leakage of bacteria from the gut resulting from damage to the intestinal lining. Research has shown that this damage happens soon after HIV infection and may not be fully reversed even after starting effective antiretroviral therapy (ART).

Suman Srinivasa, a member of Grinspoon's team at Massachusetts General, and colleagues (abstract 138) prospectively compared therelationship between gut microbes and their metabolites in 155 HIV-positive and 67 HIV-negative people without known CVD at baseline. HIV-positive participants were relatively young (mean age 47 years), had been infected for 14 years and on ART for 8 years on average, and most had undetectable viral load.

HIV-positive people weresignificantly more likely than their HIV-negative counterparts to have coronary plaque (53% vs 35%), as well as higher plaque volume. Among people with HIV, but not those without, higher levels of serum trimethylamine (TMA) -- a microbe-derived precursor of trimethylamine N-oxide (TMAO), which plays a role in cholesterol metabolism -- were associated with more plaque and higher levels of lipopolysaccharide (a bacterial toxin). TMAO has previously been linked to CVD in the HIV-negative population.

Based on these findings, the researchers concluded, "Our data demonstrate that serum, not serum TMAO, is associated with the presence of calcified and total coronary plaque burden in HIV-infected patients," an association largely independent of traditional CVD risk factors.

Several other studies at CROI looked at biomarkers of inflammation and immune activation and their association with CVD in people with HIV.

Álvaro Borges and fellow investigators with the INSIGHT SMART and ESPRIT study groups (abstract 761) found that the pro-inflammatory cytokine interleukin 6 (IL-6) was a strong predictor of non-AIDS-related clinical events and deaths, and also of CVD, among HIV-positive participants in these 2 trials -- stronger, in fact, than C-reactive protein and D-dimer were in the earlier SMART study.

A related study by Denise Hsu fromthe National Institute of Allergy and Infectious Diseases and colleagues (abstract 752), looking at 149 HIV-positive patients on suppressive ART in the SCOPE cohort, saw a link between elevated IL-6 and carotid intimal thickness, indicating buildup of plaque in the arteries supplying the brain. Likewise, Dominic Chow from the University of Hawaii and colleagues (abstract 754) found that HIV-positive people on suppressive ART had elevated levels of non-classical monocytes (characterized by unusual CD cell-surface markers) and of the pro-inflammatory cytokine MCP-1, which were associated with progression of carotid intima-media thickening. 


Researchers from the National Institutes of Health (abstract 928) reported that artery plaque build-up was greater even in adolescents and young adults (age 15-29) infected with HIV early in life compared with age-matched HIV-negative people, and was associated with CD8 T-cell activation and elevated levels of the cell adhesion molecule E-selectin.

Chronic Kidney Disease

Two research groups reported findings from studies looking at the association between CVD and kidney disease in people with HIV -- a link that is well-established in the HIV-negative general population.

Lene Ryom from the University of Copenhagen and fellow investigators with theD:A:D study group (abstract 742) assessed nearly 35,000 HIV-positive D:A:D participants  who had at least 2 estimated glomerular filtration rate (eGFR) measurements, a marker of kidney function. Over a median follow-up period of 6 years, 1033 people experienced CVD events (myocardial infarction, stroke, or related surgical procedures) during follow-up, for a rate of 5.1 events per 1000 person-years.

They found a "clear relationship" between confirmed eGFR at baseline and incidence of CVD events. While just 1.7% of people with eGFR >90 mL/min/1.73m2 progressed to CVD within 5 years, this rose to 23.4% of those with eGFR <30. While this was largely explained by age -- as older people are at higher risk for both kidney and heart disease -- a "strong trend" remained after adjusting for age, largely driven by a high CVD rate among people with eGFR <30.

"In a large contemporary cohort of HIV-positive individuals we observed a strong relationship between baseline and current confirmed impaired renal function and incident CVD," the researchers concluded. "These findings highlight the need for an intensified monitoring for all types of emerging CVD, in particular in older individuals with continuously low eGFR levels, and calls for an increased focus on applying different renal and cardiovascular preventive measures in HIV-positive individuals." 


Drozd and colleagues' analysis of more than 25,000 NA-ACCORD participants also saw a significant association between advanced chronic kidney disease (eGFR <30) and primary myocardial infarction.

What About Abacavir?

Frank Palella from Northwestern University and colleagues (abstract 749LB) presented findings another NA-ACCORD analysis looking at the association between heart attacks and use of abacavir (Ziagen, also in the Epzicom coformulation) -- a topic of ongoing debate as prior studies have produced conflicting results.

Looking at 16,733 HIV-positive adults in 7 U.S. cohorts, a total of 301 new myocardial infarctions occurred over more than 64,600 person-years of follow-up. Focusing on a subgroup of 6485 treatment-naive people starting ART that mirrored a previous D:A:D analysis, recent use of abacavir (within the past 6 months) was associated with a 71% adjusted increased risk of myocardial infarction -- approaching the nearly 2-fold risk seen in D:A:D.

However, a significant association was no longer apparent in an adjusted analysis of the full study population. Further, people who started an abacavir-containing ART regimen were more likely to have traditional and HIV-associated CVD risk factors, and the link between abacavir and myocardial infarction was diminished after taking these into account.

Traditional Risk Factors

Finally, traditional cardiovascular risk factors such as older age, smoking, abnormal blood lipid levels, diabetes, and obesity also play a role in people with HIV.

Perhaps stating the obvious, Drozd's NA-ACCORD analysis found that tobacco smoking was an independent risk factor for atherosclerosis, or build-up of plaque in arteries that can rupture and cause blockages in the heart (causing myocardial infarction) or brain (causing stroke).

A study by Sean Kelly and fellow investigators with the Multicenter AIDS Cohort Study (abstract 743) reported that cigarette smoking was the major independent risk factor for atherosclerosis. This analysis also found that HIV-positive gay and bisexual men in MACS were more likely to smoke than a group of similar at-risk HIV-negative men (31% vs 22%). Use of other substances, including alcohol and marijuana, had an inconsistent relationship with atherosclerosis.

"Our findings underscore the value of effective smoking cessation strategies targeting HIV+ persons to decrease cardiovascular disease burden," the researchers concluded.

Turning to management of elevated CVD risk, Sahera Dirajlal-Fargo from Case Western Reserve University School of Medicine and colleagues (abstract 745) looked at the relationship between physical activity and markers of cardiovascular and metabolic health and inflammation among people with HIV.

This analysis included 147 participants on ART (80% men, median age 46 years) in SATURN-HIV, a trial of rosuvastatin (Crestor) for people with HIV.They found that physical activity was significantly associated with several markers of cardio-metabolic health and inflammation. After adjusting for other factors, exercise remained independently associated with markers of cardiovascular disease including carotid intima-media thickness and endothelial function, as well as insulin resistance.

"[O]ver the 96 week study period, exercise was associated with multiple measures of subclinical vascular disease, suggesting that exercise in HIV-infected patients may improve vascular structure as well as function," the researchers concluded. "This association was evident even when accounting for statin use."

A large multicenter trial known as REPRIEVE is now underway to learn more about cardiovascular disease, its predictors and outcomes, and the benefits of statins for people with HIV.

SEE ALSO:

Predicting Cardiovascular Disease in People with HIV -- Can We Do Better?

Statins May Reduce Risk of Heart Disease in People with HIV

4/22/15

References

DB Hanna, C Ramaswamy, CP Kaplan, et al. Cardiovascular Disease Mortality Among HIV-Infected Persons, New York City, 2001-2012. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 729.

SGrinspoon. Cardiovascular Disease in HIV Patients: An Emerging Paradigm and Call to Action. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 134.

D Drozd, M Kitahata, S Heckbert, et al. Incidence and Risk of Myocardial Infarction (MI) by Type in the NA-ACCORD. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 748.

J Salinas, V Marconi, D Rimland, et al. Cumulative HIV Care Measures Highly Associated With Acute Myocardial Infarction. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 746.

S Srinivasa, V Fitch, J Lo, et al. Calcified Plaque Burden Is Associated With Serum Gut Microbiota-Generated TMA in HIV. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 138.

AH Borges, JL O'Connor, AN Phillips, et al (INSIGHT SMART and ESPRIT Study Groups). IL-6 Is a Stronger Predictor of Clinical Events Than hsCRP or D-Dimer in HIV Disease. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 761.

D Hsu, Z Hu, I Sereti, et al. IL-6 and CD8 Senescence Independently Associate With Atherosclerosis in Treated HIV. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 752.

DC Chow, JM Kagihara, GG Zhang, et al. Non-Classical Monocytes Predict Progression of Carotid Intima-Media Thickness. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 754.

JB Purdy, A Unsal, S Abd-Elmoniem, et al. T-Cell Activation and E-Selectin Associated With Coronary Plaque in HIV-Infected Youth. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 928.

L Ryom, JD Lundgren, P Reiss, et al. (D:A:D Study Group). Relationship Between Confirmed eGFR and Cardiovascular Disease in HIV-Positive Persons. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 742.

FJ Palella, KN Althoff, R Moore, et al. Abacavir Use and Risk for Myocardial Infarction in the NA-ACCORD. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 749LB.

SG Kelly, M Plankey, W Post, FJ Palella, et al. Smoking, Other Substance Use and Coronary Atherosclerosis Among HIV-Infected and Uninfected Men. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 743.

S Dirajlal-Fargo, AR Webel, B Kinley, et al. The Effect of Physical Activity on Cardiometabolic Health and Inflammation in HIV. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 745.

Some Providers Remain Reluctant to Prescribe HIV Pre-Exposure Prophylaxis

Despite a growing body of evidence showing that Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis, or PrEP, is highly effective for HIV prevention, less than half of surveyed healthcare providers are likely to prescribe it for at-risk heterosexuals or people who inject drugs -- though the likelihood approaches 80% for gay men with HIV-positive partners -- according to a study published in the April edition of HIV Specialist, the magazine of the American Academy of HIV Medicine (AAHIVM).

alt

Read more:

NIH Launches Large Trial of Cardiovascular Disease Among People with HIV

The U.S. National Heart, Lung, and Blood Institute and National Institute of Allergy and Infectious Diseases have started enrolling participants in the REPRIEVE trial, a large international study looking at cardiovascular disease risk factors, outcomes, and statin therapy for people living with HIV. A substudy of 800 participants will focus on the effects of pitavastatin (Livalo) on coronary artery disease and inflammatory biomarkers in this population.

alt

Read more:

Most Children with HIV Experience CD4 Cell Recovery after Starting Antiretroviral Therapy

Children with perinatal HIV infection who start antiretroviral therapy (ART) typically experience good recovery of CD4 T-cells, but the likelihood of reaching 500 cells/mm3 or more is higher for those with less immune suppression prior to treatment initiation, according to a study published in the March 27 edition of AIDS.

alt

Read more:

CROI 2015: Cardiovascular Risk Factors for HIV-Positive People

Consistent with past research, an analysis from New York City has shown that people with HIV are at higher risk for death due to cardiovascular disease, although this risk is declining, according to a report at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI). Several other studies looked at cardiovascular risk factors in this population, including inflammatory biomarkers, chronic kidney disease, gut bacteria, and use of abacavir.

alt

Read more:

CROI 2015: Cardiovascular Disease Among People with HIV

People living with HIV are at greater risk for cardiovascular disease (CVD) and events such as heart attacks. Several presentations at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) looked at CVD risk factors, how to better predict it, and approaches to risk reduction.

Predicting Cardiovascular Disease in People with HIV -- Can We Do Better?

Cardiovascular Risk Factors for HIV-Positive People

Statins May Reduce Risk of Heart Disease in People with HIV

4/10/15

 

alt

Broadly Neutralizing Antibody Reduces HIV Viral Load in Early Human Study

A novel broadly neutralizing monoclonal antibody known as 3BNC117 inhibited HIV replication its the first Phase 1 clinical trial in humans, according to a letter in the April 8 online edition of Nature. A single infusion of 3BNC117 reduced HIV viral load by up to 2.5 logs and viremia remained significantly lower for 28 days, the researchers wrote.

alt

Read more:

CROI 2015: Predicting Cardiovascular Disease in People with HIV -- Can We Do Better?

Four existing models used to predict risk of cardiovascular disease (CVD) underestimated that risk in large cohorts of people living with HIV, according to research presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. Other studies suggested that even without that underestimation being taken into account, many HIV-positive people are currently undertreated with statins, which could protect them from cardiovascular events like myocardial infarction.

alt

Read more:

Long-time Researcher Discusses Myths About HIV Pathogenesis, Treatment, and Cure

Over the 3 decades of the epidemic a number of misconceptions have arisen about HIV infection, how the immune system fights the virus, and how best to treat and potentially cure it, along with a number of important questions that remain unanswered, according to an opinion article in the April 13 advance edition of Trends in Molecular Medicine by Jay Levy from the University of California at San Francisco, one of the first researchers to study HIV. The trend toward earlier antiretroviral therapy and treatment-as-prevention are among the issues he contests.

alt

Read more:

Gilead Requests Approval of Tenofovir Alafenamide Dual Combination Pill

Gilead Sciences has requested U.S. Food and Drug Administration approval of a combination pill containing emtricitabine plus tenofovir alafenamide (TAF), a new formulation that is easier on the kidneys and bones, according to a company press release. If approved, the new coformulation could take the place of Truvada for HIV treatment, though its effectiveness for pre-exposure prophylaxis, or PrEP, is not yet known.

alt


Tenofovir disoproxil fumarate or TDF (Viread, also in Truvada, Atripla, and other Gilead single-tablet regimens) is one of the most widely used antiretroviral drugs. TAF is a pro-drug that delivers the active agent to HIV-infected cells more efficiently than TDF. TAF produces adequate intracellular drug levels with lower doses, which means lower concentrations in the blood plasma and less drug exposure for organs and tissues.

As reported at the recent 2015 Conference on Retroviruses and Opportunistic infections, Phase 3 studies have shownthat a single-tablet regimen containing TAF, emtricitabine, elvitegravir, and cobicistat was equally effective at suppressing HIV but hadless detrimental effects on the kidneys and bones than the existing Stribild coformulation containing TDF.

Below is an edited excerpt from a Gilead press release describing the TAF/emtricitabine new drug application. The company has also requested approval of the 4-drug single-tablet regimen described above, and stand-alone TAF is being developed as a treatment for hepatitis B.

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment

Potential New Backbone for Future HIV Therapy Combinations

Foster City, Calif. -- April 7, 2015 -- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) (F/TAF) for the treatment of HIV-1 infection in adults and pediatric patients age 12 years and older, in combination with other HIV antiretroviral agents.

TAF is a novel nucleotide reverse transcriptase inhibitor(NRTI) that has demonstrated high antiviral efficacy at a dose less than one-tenth that of Gilead’s Viread (tenofovir disoproxil fumarate, TDF), as well as improved renal and bone laboratory parameters as compared to TDF in clinical trials.

"Gilead has a long history of innovating HIV treatments, and with F/TAF we have the potential to further optimize therapies for HIV patients who face a lifetime of antiretroviral treatment," said Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences. "With its high antiviral efficacy and favorable safety profile, F/TAF may offer an improved backbone for a new generation of HIV regimens."

Today’s filing is Gilead’s second F/TAF-based NDA submitted to the FDA for review.  In November 2014, Gilead filed an NDA for an investigational once-daily single tablet regimen containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and TAF 10 mg (E/C/F/TAF). Under the Prescription Drug User Fee Act, the FDA has set a target action date of November 5, 2015. Additionally, a Marketing Authorization Application in the European Union for E/C/F/TAF was fully validated on December 23, 2014.

The F/TAF NDA is supported by data from Phase 3 clinical studies evaluating the safety and efficacy of E/C/F/TAF for the treatment of HIV-1 infection among treatment-naive adults, in which the F/TAF-based regimen (administered as E/C/F/TAF) resulted in non-inferior efficacy and improved renal and bone laboratory parameters as compared to F/TDF-based therapy (administered as E/C/F/TDF or Stribild).The NDA is also supported by data from additional Phase 3 studies evaluating the F/TAF-based regimen (administered as E/C/F/TAF) among treatment-naive adolescents, virologically suppressed adults who switched regimens, and adults with mild-to-moderate renal impairment. Lastly,bioequivalence studies demonstrated that the formulation of the fixed-dose combinations of F/TAF achieved the samedruglevelsin the blood as in E/C/F/TAF.

The recommended dose of F/TAF is 200/25 mg; if it is used in combination with a protease inhibitor that is administered with either ritonavir or cobicistat, the recommended dose is 200/10 mg.

Additional F/TAF-based regimens for HIV treatment are currently in development. In December 2014, Gilead announced the expansion of its existing agreements with Janssen Sciences Ireland UC for the development and commercialization of two new investigational once-daily single tablet regimens containing F/TAF. One combines F/TAF with Janssen’s rilpivirine. The other regimen contains F/TAF, cobicistat and Janssen’s darunavir.

Gilead plans to submit a regulatory application for F/TAF in the European Union in the second quarter of 2015.

F/TAF-based regimens are investigational products and have not been determined to be safe or efficacious.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.  The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

4/8/15

Source

Gilead Sciences. Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment. Press release. April 7, 2014.

CROI 2015: Daily PrEP Leads to Better Adherence and Protective Drug Levels in Women

HIV-negative African women assigned to take once-daily Truvada for HIV pre-exposure prophylaxis (PrEP) achieved better adherence than those assigned to take PrEP twice-weekly or before and after sex, according to findings from the HPTN 067 trial presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

Read more:

CROI 2015: Levonorgestrel Contraception May Be Less Effective for Women Taking Efavirenz

African women who took efavirenz as part of a combination antiretroviral regimen were more likely to become pregnant while using the levonorgestrel implant, likely due to a drug interaction that lowers levels of the hormonal contraceptive, according to a presentation at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

Read more:

Women in PrEP Trial Feared Having to Leave Study if They Reported Low Adherence

Post-study interviews and computer questionnaires conducted with former participants in the Fem-PrEP trial of pre-exposure prophylaxis (PrEP) that reported zero effectiveness show that the women concealed their low adherence because -- despite reassurances from researchers -- they feared they would be asked to leave the study, according to a report in the April 2015 Journal of Acquired Immune Deficiency Syndromes.

alt

Read more:

Trial of CCR5-Deleted Stem Cell Gene Therapy for HIV Gets FDA Go-Ahead

The U.S. Food and Drug Administration (FDA) has given approval to proceed with a clinical trial of a gene therapy method that cuts the gene for the CCR5 coreceptor out of stem cells, making them resistant to HIV entry, the California Institute for Regenerative Medicine (CIRM) recently announced.

alt

Read more:

HIV Risk Behavior Remains Common Among People Who Inject Drugs in U.S.

An analysis from the CDC's National HIV Behavioral Surveillance system found that 11% of injection drug users in 20 U.S. cities were HIV-positive in 2012, according to a report in the March 20 Morbidity and Mortality Weekly Report. One-third of the interviewees reported sharing used injection equipment, putting them at risk for acquiring HIV and hepatitis B and C, while a majority reported sex without condoms.

alt

Read more:

Valacyclovir May Reduce HIV Viral Load Even in People Without Herpes

The antiviral drug valacyclovir (Valtrex and generics), used to treat herpes simplex virus type 2 (HSV), led to a decrease in HIV viral load even among individuals who did not have genital herpes, according to a small study reported in the March 3 advance edition of Clinical Infectious Diseases.

alt

Read more:

DHHS Updates Antiretroviral Treatment Guidelines for Adults and Children

The U.S. Department of Health and Human Services (DHHS) has released updated versions of its antiretroviral treatment guidelines for adults and adolescents, and for children with HIV. The new adult guidelines include revised recommendations for first-line antiretroviral therapy (ART) as well as management of treatment-experienced patients. The revised pediatric guidelines include a discussion of very early treatment for HIV-infected infants.

alt

Read more:

CROI 2015: Experimental Agents Reverse HIV Latency, Help Immune System Fight Infected Cells

Researchers at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle presented data on several experimental agents that may play a role in achieving a "functional cure" for HIV, or prolonged remission without disease progression. These include drugs that reactivate the latent HIV reservoir, interfere with expression of viral DNA, and help the immune system target HIV-infected cells.

alt

Read more: